Back

Efficacy of anticoagulation in atrial fibrillation: evidence from 36 years of randomized controlled trials - a meta-analysis

31 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation in atrial fibrillation: striking the balance Stroke in Atrial Fibrillation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Patrick Sumariva

Rio Do Sul (Brazil)

3 More presentations in this session

Presentation thumbnail
Standard modifiable cardiovascular risk factors and prognostic outcomes in non-valvular atrial fibrillation on oral anticoagulants
Doctor H. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry
Associate Professor M. Gawalko (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Competing risks of ischemic stroke, intracranial bleeding, and mortality in patients with atrial fibrillation and prior intracranial hemorrhage without an anticoagulation regimen
Doctor P. Tiili (Helsinki, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation in atrial fibrillation: striking the balance

The Event

Event poster

ESC Congress 2025

31 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
The role of anticoagulation in atrial high-rate episodes: a meta-analysis
thumbnail
Congress Presentation
Safety of discontinuing anticoagulation after atrial fibrillation ablation
thumbnail
Congress Presentation
The efficacy and safety of edoxaban compared to warfarin in patients with atrial fibrillation with different clinical phenotypes: a meta-analysis of randomized controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources